Department of Diagnostic Reagents
Development, Otsuka Pharmaceutical Co., Ltd., Tokushima 771-01, Japan
Received 24 July 1997/Returned for modification 8 September
1997/Accepted 26 September 1997
Urine and serum samples from 89 healthy volunteers and three
healthy individuals who underwent rubella vaccination were tested for
immunoglobulin G (IgG), IgA, and IgM to rubella virus (RV) by
enzyme-linked immunosorbent assay methods. Subjects with positive (n = 68) or negative (n = 21) results
for serum IgG were exactly the same as those with the corresponding
results for urinary IgG. Both urinary and serum IgG levels remained
elevated from the 3rd or 4th week after vaccination until the end of
the study. Both urinary IgA and serum IgM levels tended to increase
rapidly between the 3rd and 5th week and then gradually decrease until
the end of the study, but the levels of both remained positive except for one sample each at the end (26th week). On the other hand, the
ratio of anti-RV IgA titer to anti-RV IgG titer in urine (urinary anti-RV IgA/IgG ratio) increased rapidly between the 3rd and 4th week
after vaccination and then rapidly returned to the ratio levels of the
subjects positive for serum IgG from among the healthy volunteers. In
summary, detection of urinary anti-RV IgG should be useful for
screening for previous RV infection, and measurement of urinary anti-RV
IgA/IgG ratio might be useful for diagnosing recent infection.
 |
INTRODUCTION |
Infection by rubella virus (RV), the
sole member of the genus Rubivirus of the family
Togaviridae, is usually a self-limited disease that occurs
mainly between infancy and puberty. Symptoms are usually mild and
similar to those of other viral diseases with rash such as measles,
scarlatina, infectious erythema, exanthema subitum, and infectious
mononucleosis (17). Therefore, differential diagnosis of
these is required, and blood samples are usually used for this purpose.
However, it is difficult to collect blood samples from infants and
young children. Although urine-based antibody tests have been developed
for screening of infectious diseases (5, 10, 15),
saliva-based antibody tests have been developed only for RV (13,
14). More importantly, the fetuses of women infected with RV
during the first trimester of pregnancy have a high rate of congenital
rubella syndrome (17). To reduce the risk of development of
congenital rubella syndrome, a hemagglutination inhibition (HI) test
has routinely been performed to detect anti-RV antibody in serum in
pregnant women. This method is useful for screening for infection but
is not useful for determining when viral infection occurred.
Enzyme-linked immunosorbent assay (ELISA) for anti-RV immunoglobulin M
(IgM) in serum is widely used for detection of recent infection.
Anti-RV IgM has been reported to appear in serum from the 2nd or 3rd
week after infection and to disappear by the end of the 1st or 2nd
month (3, 4, 6-8, 16). Subsequently, however, it has also
been demonstrated that IgM can be detected in serum for longer periods,
up to a year after infection (1, 2, 11, 12). Elevation of HI
titers for a period of 1 or 2 weeks has also been used for detection of
recent infection; however, specimens must be collected at intervals of
more than 1 week for the assay. In this study, we have for the first
time developed an ELISA method for detection of anti-RV IgG and IgA
antibodies in human urine and compared its usefulness with that of a
commercially available kit for serum antibody detection. We also
examined the urinary anti-RV IgA/IgG ratio for detection of recent
infection, using vaccinated subjects.
 |
MATERIALS AND METHODS |
Specimens.
Random single-void urine and serum samples were
collected at the same time from 89 healthy volunteers, including 83 males (21 to 51 years old; mean age, 36.2 years) and 6 females (21 to 37 years old; mean age, 27.3 years); five of the females had undergone rubella vaccination when they were 13 or 14 years old. In addition, three healthy males (31 or 32 years old) underwent one injection of
rubella vaccine (TCRB19 strain; Chiba Serum Institute, Chiba, Japan),
and random single-void urine and serum samples were collected from them
before vaccination and at several points up to the 26th week after
vaccination. Unfortunately, we failed to collect samples from one
subject at the 4th week and from another subject at the 22nd week.
ELISA for anti-RV antibodies in urine.
Wells of microtiter
plates (Nunc, Roskilde, Denmark) were coated with 100 µl of a
1-µg/ml RV antigen solution (Biodesign, Kennebunk, Maine) in
Dulbecco's phosphate-buffered saline, pH 7.4 (PBS) (Nissui
Pharmaceutical, Tokyo, Japan). After overnight incubation at 4°C, the
unoccupied binding sites were blocked by incubation overnight at 4°C
with Dulbecco's PBS containing 1% bovine serum albumin (Seikagaku
Kogyo, Tokyo, Japan) and 5% sucrose (Wako Pure Chemicals, Osaka,
Japan). The plates were air dried after aspiration of the blocking
solution and stored at 4°C with desiccant until use. The plates were
incubated with 20 µl of 0.2 M Tris chloride buffer, pH 7.3, containing 0.14 M sodium chloride, 2% casein (Wako Pure Chemicals),
0.5% bovine serum albumin, 0.05% Tween 20, and 0.1% sodium azide and
with 100-µl urine samples at 37°C for 1 h. Plates were then
rinsed with PBS containing 0.05% Tween 20 and 0.05% sodium azide
(PBS-T) and incubated at 37°C for 1 h with either 100 µl of
horseradish peroxidase-conjugated anti-human IgG (Jackson, West Grove,
Pa.) or horseradish peroxidase-conjugated anti-human IgA antibody
(Jackson). The plates were then rinsed with PBS-T and incubated with
100 µl of 3,3',5,5'-tetramethylbenzidine soluble solution (Scytek
Laboratories, Logan, Utah) for color development. The reaction was
stopped by adding 100 µl of stop solution for
3,3',5,5'-tetramethylbenzidine (Scytek Laboratories). Optical density
(OD) was measured at 450 nm by using a plate reader (Molecular Devices
Vmax, Sunnyvale, Calif.). The mean value plus 3 standard deviations
calculated from the test results for subjects who had negative results
for serum IgG was used as a cutoff value for each urinary assay. The
cutoff indices (ODsample/ODcutoff) were used
for evaluation of each urinary assay, and the anti-RV IgA/IgG ratios
were calculated by using the cutoff indices. The mean value plus 5 standard deviations calculated from the anti-RV IgA/IgG ratios of the
healthy volunteers who had positive results for serum IgG was used as a
cutoff value for evaluation of the urinary anti-RV IgA/IgG ratio.
ELISA for anti-RV antibodies in serum.
Anti-RV IgG and IgM
antibodies in serum were measured by using commercially available ELISA
kits (Denka Seiken, Tokyo, Japan) in accordance with the
manufacturer's instructions.
 |
RESULTS |
Detection of urinary anti-RV IgG and IgA antibodies in healthy
volunteers.
Serum and urine samples were collected at the same
time from 89 healthy volunteers, and levels of serum IgG, urinary IgG, and urinary IgA against RV were measured by the ELISA method developed in this study or the commercially available ELISA kit (serum IgG). When
subjects were divided into a positive group (n = 68)
and negative group (n = 21) based on the results of the
serum IgG assay, both the urinary IgG and the urinary IgA levels were
significantly higher (P < 0.001 [unpaired
t test]) in the positive group than in the negative group
(Fig. 1). Notably, both the sensitivity and the specificity of the urinary IgG assay were perfect (100%) compared to those for serum IgG, indicating that urine samples can be
used as an alternative to serum samples for RV antibody screening. On
the other hand, only 56 of 68 (82%) subjects in the serum IgG
assay-positive group had positive results for urinary IgA. The urinary
IgA assay was therefore not useful for screening.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 1.
Levels of urinary IgG and IgA antibody to RV in healthy
volunteers. The division of subjects into positive and negative groups
was based on serum IgG levels. Horizontal lines indicate the cutoff
value. (A) Urinary IgG level; (B) urinary IgA level.
|
|
Changes in urinary and serum anti-RV antibody levels after
vaccination.
Three healthy subjects underwent rubella vaccination,
and their levels of urinary IgG and IgA antibody and serum IgG and IgM antibody against RV were measured by using samples collected before and
at regular intervals after vaccination (Fig.
2). The serum and urinary IgG levels
remained elevated from the 3rd or 4th week after vaccination. The serum
IgM and urinary IgA levels rapidly increased between the 3rd and 5th
week and then decreased gradually but remained positive for a long
time, as shown in Fig. 2. Individual urinary antibody levels fluctuated
during the test period due to variability in the concentrations of
urine samples. In addition, individual profiles of urinary IgG levels
differed considerably from those of urinary IgA levels between the 3rd
and 8th week, while these profiles were quite similar to each other
after the 9th week. This type of relationship was not observed between
serum IgG and IgM levels.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 2.
Changes over time in anti-RV antibody levels in urine
and serum after vaccination. Changes over time in titers of urinary IgG
(A), urinary IgA (B), serum IgG (C), and serum IgM (D) against RV are
indicated. , positive sample; , negative sample. Samples with
indeterminate values in serum assays were classified as positive.
Dashed portions of the curves indicate failure to collect a sample.
Horizontal lines indicate cutoff values. Circles, squares, and
triangles correspond to three subjects.
|
|
Changes in urinary anti-RV IgA/IgG ratios after vaccination.
Anti-RV IgA/IgG ratios for the urine samples from the vaccinated
subjects were calculated and compared with the ratios calculated by
using subjects positive for serum IgG from among the healthy volunteers
(Fig. 3). The ratios increased rapidly
between the 3rd and 4th week after vaccination and then decreased
rapidly to the levels found for the positive volunteers. All the ratios during the period from the 3rd to the 8th week were beyond the cutoff
value except for one sample at the 7th week. None of the ratios for the
samples collected after the 9th week or those for the samples from the
positive volunteers who were assumed to have been infected or
vaccinated with RV in the past were beyond the cutoff value.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 3.
Changes over time in ratios of the titer of IgA antibody
to RV to the titer of IgG antibody to RV in urine after vaccination,
compared with the ratios for IgG-positive subjects (PS) from among the
healthy volunteers. Closed symbols, samples positive for urinary
anti-RV IgG or IgA; open symbols, samples negative for urinary anti-RV
IgG and IgA. Dashed portions of the curves indicate failure to collect
a sample. The horizontal line indicates the cutoff value of the ratio.
Circles, squares, and triangles correspond to three subjects.
|
|
 |
DISCUSSION |
Most rubella patients are infants or young children. However, it
is difficult to collect blood samples from small children for detection
of anti-RV antibody. The urine-based assay methods developed in this
study should be helpful in solving this problem, since urine samples
were demonstrated to be a useful alternative to serum samples for
detection of anti-RV IgG antibody. Urinary anti-RV IgA antibody was
also detected in many samples, but the sensitivity was lower than those
for serum IgG and urinary IgG antibodies. However, urinary IgA antibody
levels as well as serum IgM antibody levels increased earlier than
urinary IgG and serum IgG after rubella vaccination. High urinary IgA
levels were maintained for a long time as observed for serum IgA
(2, 9, 11), and the individual urinary IgA levels fluctuated
markedly during the test period due to variability in urine
concentration. Therefore, urinary IgA might not be a useful marker for
detection of recent RV infection. Although serum IgM is a marker of
recent infection, positive levels of serum IgM were maintained for a
long time after vaccination, as shown in Fig. 2. This observation has
been reported not only for vaccine-induced infection but also for
natural infection (1, 2, 11, 12). It is also recommended
that an increase in the HI test titer in 1 or 2 weeks should be tested
when recent infection is suspected.
On the other hand, urinary anti-RV IgA/IgG ratios dramatically
increased and then decreased, with a peak at the 4th week in the
primary period after vaccination, even though urinary IgA and IgG
levels remained positive at least until the 26th week after vaccination
in most cases. This was caused by the gradual increase in urinary IgG
level and rapid increase in urinary IgA level as a primary antibody
response. Ratios did not fluctuate markedly because the effects of
variability in concentration in urine must have been eliminated by
division of IgA level by IgG level for the same urine sample in the
calculation of ratios.
Serum anti-RV IgM/IgG ratio was not a better indicator of recent
infection than urinary IgA/IgG ratio (data not shown). Although serum
IgG ELISA is usually performed as a direct assay using antigen-coated microplates, serum IgM ELISA requires absorption of IgG in serum samples as pretreatment or a capture assay method using anti-human IgM
antibody-coated plates. Poorer indication of recent infection by serum
IgM/IgG ratio may be due to differences in assay methods. On the other
hand, the ELISAs developed for urinary IgG and IgA in this study are
direct assays using antigen-coated microplates without any pretreatment
including sample dilution and require common materials and procedures
except for enzyme conjugates (anti-human IgG or anti-human IgA). The
common assay method may demonstrate the usefulness of the urinary
IgA/IgG ratio for detection of recent infection.
In conclusion, we have developed for the first time ELISA methods for
detection of urinary IgG and IgA antibodies to RV. The assay methods
devised are simple and do not require any pretreatment of samples such
as absorption of IgG or dilution of samples prior to setup. Random
single-void urine samples are extremely easy to collect from infants
and young children. Our findings suggest that direct testing of urine
samples for RV-specific IgG provides an efficient alternative to
serum-based assays. In addition, measurement of the ratio of IgA titer
to IgG titer in the same urine sample may permit more accurate
diagnosis of recent RV infection sooner after infection than
serum-based IgM assays. Therefore, our urine-based assays should be
useful for screening for RV-specific antibody, and they may also be
helpful in diagnosing recent infection with RV. To confirm the
usefulness of our assays, further examination using samples from
patients who were recently and naturally infected with RV will be
necessary.
| 1.
|
Al-Nakib, W.,
J. M. Best, and J. E. Banatvala.
1974.
Rubella-specific IgM and a new inhibitor.
Br. Med. J.
iii:579.
|
| 2.
|
Al-Nakib, W.,
J. M. Best, and J. E. Banatvala.
1975.
Rubella-specific serum and nasopharyngeal immunoglobulin responses following naturally acquired and vaccine-induced infection.
Lancet
i:182-185.
|
| 3.
|
Best, J. M.,
J. E. Banatvala, and D. Watson.
1969.
Serum IgM and IgG responses in postnatally acquired rubella.
Lancet
ii:65-68.
|
| 4.
|
Burgin-Wolff, A.,
R. Hernandy, and M. Just.
1971.
Separation of rubella IgM, IgA and IgG antibodies by gel filtration on agarose.
Lancet
ii:1278-1280.
|
| 5.
|
Cohen, D.,
N. Orr,
G. Robin,
R. Slepon,
S. Ashkenazi,
I. Ashkenazi, and J. Shemer.
1996.
Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination.
Clin. Diagn. Lab. Immunol.
3:451-455[Abstract].
|
| 6.
|
Cradoc-Watson, J. E.,
M. K. S. Ridehalgh,
M. S. Bourne, and E. M. Vandervelde.
1973.
Nasal immunoglobulin responses in acute rubella determination by the immunofluorescent technique.
J. Hyg. Camb.
71:603-617[Medline].
|
| 7.
|
Desmyter, J.,
M. A. South, and W. E. Rawls.
1971.
The IgM antibody response in rubella during pregnancy.
J. Med. Microbiol.
4:107-114[Medline].
|
| 8.
|
Haire, M., and D. S. M. Hadden.
1972.
Rapid diagnosis of rubella by demonstrating rubella-specific IgM antibodies in the serum by indirect immunofluorescence.
J. Med. Microbiol.
5:237-242[Medline].
|
| 9.
|
Halonen, P.,
O. Halonen, and M.-T. Matikainen.
1979.
IgA antibody response in acute rubella determined by solid-phase radioimmunoassay.
J. Hyg. Camb.
83:69-75.
|
| 10.
|
Martinez, P.,
R. Ortiz de Lejarazu,
J. M. Eiros,
J. De Benito, and A. Rodriguez-Torres.
1996.
Urine samples as a possible alternative to serum for human immunodeficiency virus antibody screening.
Eur. J. Clin. Microbiol. Infect. Dis.
15:810-813[Medline].
|
| 11.
|
Ogra, P. L.,
D. Kerr-Grant,
G. Umana,
J. Dzierba, and D. Werntraub.
1971.
Antibody response in serum and nasopharynx after naturally acquired and vaccine induced infection with rubella virus.
N. Engl. J. Med.
285:1333-1339.
|
| 12.
|
Pattison, J. R.,
D. S. Dane, and J. E. Mace.
1975.
Presence of specific IgM after natural infection with rubella virus.
Lancet
i:185-187.
|
| 13.
|
Perry, K. R.,
D. W. G. Brown,
J. V. Parry,
S. Panday,
C. Pipkin, and A. Richards.
1993.
Detection of measles, mumps, and rubella antibodies in saliva using antibody capture radioimmunoassay.
J. Med. Virol.
40:235-240[Medline].
|
| 14.
|
Thieme, T.,
S. Piacentini,
S. Davidson, and K. Steingart.
1994.
Determination of measles, mumps, and rubella immunization status using oral fluid samples.
JAMA
272:219-221[Abstract].
|
| 15.
|
Uronovitz, H. B.,
W. H. Murphy,
T. D. Gottfried, and A. E. Friedman-Kien.
1996.
Urine-based diagnostic technologies.
Trends Biotechnol.
14:361-364[Medline].
|
| 16.
|
Vesikari, T., and A. Vaheri.
1968.
Rubella: a method for rapid diagnosis of a recent infection by determination of the IgM antibodies.
Br. Med. J.
i:221-223.
|
| 17.
|
Wolinsky, J. S.
1990.
Rubella virus, p. 815-840.
In
B. N. Fields, and D. M. Knipe (ed.), Virology. Raven Press, New York, N.Y.
|